Loading clinical trials...

Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

A Phase 2, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Televancin (TD-6424) for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

NCT00062647•Cumberland Pharmaceuticals

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•\- Documented S. aureus bacteremia

Exclusion Criteria

•\- Patients who had received or would have received more than 72 hours of potentially effective systemic antistaphylococcal therapy within 7 days prior to randomization. The following agents were considered potentially effective antistaphylococcal therapy: antistaphylococcal penicillins (including nafcillin, oxacillin, or cloxacillin), cephalosporins, fluoroquinolones, glycopeptides (including vancomycin and teicoplanin) and linezolid

Locations (1)

Wellstar Infectious Disease

Marietta, Georgia, United States

Key Dates

Start Date

August 1, 2003

Primary Completion Date

August 1, 2006

Completion Date

August 1, 2006

Last Updated

January 16, 2019

Enrollment

ACTUAL participants

Conditions

Gram-Positive Bacterial Infections

Interventions

Telavancin

DRUG

Vancomycin, nafcillin, oxacillin, or cloxacillin

DRUG

Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease

NCT05824988

Mycobacterium Avium ComplexMycobacterium Avium-Intracellulare Infection+2 more

View study

COMPLETEDNA

Clinical Decision Support Tool for Vancomycin Dosing in Children

NCT04911270

Gram-Positive Bacterial InfectionsVancomycin+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 16, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

Inclusion Criteria

Exclusion Criteria

Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease

Clinical Decision Support Tool for Vancomycin Dosing in Children

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection

Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings

Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)

Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects